TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV, L3
Market cap: $39.4B (2/09/2026)
Price: $34.37
Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
To Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Teva Extends Maturity Date of Revolving Credit Agreement to 2028
Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Earnings Release
Shareholder votes
News, Securities Holder Rights or Indentures, Description of Registrant's Securities, Legal Opinion
Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes
FY 2024
Q3
Q1
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Specialized Disclosure Report
Free Writing Prospectus